MC 1046
(Synonyms: Impurity A of Calcipotriol) 目录号 : GC16982
MC 1046(Impurity A of Calcipotriol) 是 Calcipotriol 的杂质； Calcipotriol (MC 903; Calcipotriene) 是 VDR 样受体的配体。
Cas No.:126860-83-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
MC 903 has been found to be a potent inducer of cell differentiation and to inhibit proliferation and DNA-synthesis of cells possessing the receptor for 1,25(OH)2D3. MC 1046 is the metabolite of calcipotrioI (MC 903), which is a novel analogue of the physiologically active metabolite of vitamin D3.
In vitro: The biological effects on the U937 cells of the two major metabolites of MC 903 (MC 1046 and MC 1080) were investigated. Results showed that the metabolites had effects that were more than 100 times weaker than those of the parent compound [1].
In vivo: MC 903 is a novel analogue of the physiologically active metabolite of 1,25(OH)2D3. Unlike the similar effects on cell proliferation and cell differentiation in vitro, MC 903 has 100-200 times less effect on calcium metabolism in vivo. Moreover, rat study indicats that the effect of MC 903 on proliferative disorders, its fast elimination and the formation of inactive metabolites makes MC 903 suitable for topical treatment of psoriasis [1].
Clinical trial: No clinical data are available for MC 1046 and its analogues.
Reference:
[1] Kissmeyer AM, Binderup L. Calcipotriol (MC 903): pharmacokinetics in rats and biological activities of metabolites. A comparative study with 1,25(OH)2D3. Biochem Pharmacol. 1991;41(11):1601-6.
| Cas No. | 126860-83-1 | SDF | |
| 别名 | Impurity A of Calcipotriol | ||
| 化学名 | (E,4R)-4-[(1R,4E,7aR)-4-[(2Z)-2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-1-cyclopropylpent-2-en-1-one | ||
| Canonical SMILES | CC(C=CC(=O)C1CC1)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C | ||
| 分子式 | C27H38O3 | 分子量 | 410.59 |
| 溶解度 | Soluble in DMSO | 储存条件 | 4°C, protect from light, stored under nitrogen,unstable in solution, ready to use. |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4355 mL | 12.1776 mL | 24.3552 mL |
| 5 mM | 0.4871 mL | 2.4355 mL | 4.871 mL |
| 10 mM | 0.2436 mL | 1.2178 mL | 2.4355 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。